In reference to the 1-A offering, here is a similar offering from another one of CFO Bailey's OTC company (SR*X). It was preliminary offered at 1 billion shares @.0025. It's important to read the details in this offering as I believe similar terms will eventually be applied to the ONCI offering.
On July 9, 2018 the Company filed a Preliminary (Draft) Offering Circular (Form 1-A) with the SEC seeking a capital raise, through Regulation A. The Draft filing was updated on August 9,2018 and on September 21,2018 respectively, although the basic terms of the offering remained substantially unchanged. It is anticipated that the actual offering price will be substantially amended in the final filing in accordance with the then approximate market price of the Company’s common shares at that date. At the date of this filing the Company is awaiting the receipt of formal approval to the offering from the SEC before it can become effective. As an inducement to the financial advisor to provide advice on the Regulation A offering, on February 8, 2018 the Company issued to that advisor a warrant for 30 million common shares, which can be exercised in part or in whole through February 28, 2023. The Warrants can be exercised at the lower of the fixed exercise price of $ 0.001 per share or 50% of the lowest traded price of the common stock in the 20 consecutive trading days prior to exercise
===========================
It's important to note that it's been almost 9 months since the 1-A was disclosed and they still haven't received formal approval from the SEC. The price has been cut in half since July 9.
Could a similar timeline and changes be in store for ONCI/HEXA?
